Ascentage Pharma Group International (HKG:6855)
Hong Kong · Delayed Price · Currency is HKD 33.60
-1.18 (-3.39%)
Aug 20, 2026, 4:09 PM HKT
HKG:6855 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 642.64 | 574.12 | 980.65 | 221.98 | 209.71 | 27.91 | |
Revenue Growth | 64.52% | -41.45% | 341.77% | 5.85% | 651.38% | 124.18% |
Cost of Revenue | 39.01 | 48.94 | 29.09 | 30.54 | 22 | 3.33 |
Gross Profit | 603.62 | 525.18 | 951.57 | 191.44 | 187.71 | 24.58 |
Selling, General & Admin | 707.73 | 599.92 | 383.12 | 376.46 | 328.02 | 191.26 |
Research & Development | 1,306 | 1,137 | 947.25 | 706.97 | 743.1 | 766.49 |
Operating Expenses | 2,014 | 1,737 | 1,330 | 1,083 | 1,071 | 957.75 |
Operating Income | -1,410 | -1,212 | -378.8 | -891.99 | -883.41 | -933.17 |
Interest Expense | -53.09 | -54.07 | -64.46 | -96.06 | -52.79 | -16.73 |
Interest & Investment Income | 82.13 | 82.13 | 37.84 | 32.41 | 9.73 | 7.11 |
Earnings From Equity Investments | 0.29 | 0.31 | -0.28 | 1.08 | -0.28 | - |
Currency Exchange Gain (Loss) | -10.16 | -10.16 | 6.69 | 1.62 | -2.64 | 9.91 |
Other Non Operating Income (Expenses) | -61.67 | -40.92 | 4.63 | 20.78 | 49.91 | 139.47 |
EBT Excluding Unusual Items | -1,453 | -1,235 | -394.37 | -932.17 | -879.48 | -793.41 |
Gain (Loss) on Sale of Investments | -1.13 | -1.13 | -0.83 | -0.7 | -9.77 | -20.89 |
Gain (Loss) on Sale of Assets | -0.02 | -0.02 | -0.05 | 0 | 2.07 | -0.03 |
Other Unusual Items | - | - | - | - | - | -17.92 |
Pretax Income | -1,454 | -1,236 | -395.26 | -932.86 | -887.17 | -832.25 |
Income Tax Expense | 15.05 | 6.94 | 10.43 | -7.15 | -4.25 | -49.83 |
Earnings From Continuing Operations | -1,469 | -1,243 | -405.68 | -925.71 | -882.92 | -782.42 |
Minority Interest in Earnings | 0.47 | 0.22 | 0.25 | 0.08 | - | - |
Net Income | -1,469 | -1,243 | -405.43 | -925.64 | -882.92 | -782.42 |
Net Income to Common | -1,469 | -1,243 | -405.43 | -925.64 | -882.92 | -782.42 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 372 | 356 | 302 | 282 | 264 | 255 |
Shares Outstanding (Diluted) | 372 | 356 | 302 | 282 | 264 | 255 |
Shares Change | 13.72% | 17.90% | 7.00% | 7.07% | 3.56% | 17.93% |
EPS (Basic) | -3.95 | -3.49 | -1.34 | -3.28 | -3.35 | -3.07 |
EPS (Diluted) | -3.95 | -3.49 | -1.34 | -3.28 | -3.35 | -3.07 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -1,343 | -1,202 | -135.65 | -772.19 | -857.2 | -1,040 |
Free Cash Flow Per Share | -3.61 | -3.37 | -0.45 | -2.73 | -3.25 | -4.08 |
Gross Margin | 93.93% | 91.48% | 97.03% | 86.24% | 89.51% | 88.08% |
Operating Margin | -219.48% | -211.14% | -38.63% | -401.83% | -421.25% | -3343.50% |
Profit Margin | -228.54% | -216.47% | -41.34% | -416.98% | -421.02% | -2803.38% |
Free Cash Flow Margin | -208.93% | -209.31% | -13.83% | -347.86% | -408.75% | -3726.60% |
EBITDA | -1,337 | -1,138 | -298.87 | -812.82 | -835.99 | -915.99 |
EBITDA Margin | -208.03% | -198.15% | -30.48% | - | - | - |
D&A For EBITDA | 73.57 | 74.56 | 79.94 | 79.17 | 47.42 | 17.18 |
EBIT | -1,410 | -1,212 | -378.8 | -891.99 | -883.41 | -933.17 |
EBIT Margin | -219.48% | -211.14% | -38.63% | - | - | - |